TP53 and colorectal carcinoma: Yu et al, for example, showed in 2002 that tumors derived from p53(+/+) HCT116 colorectal carcinoma cells were far more sensitive to VEGF receptor targeted therapy than tumors generated from isogenic p53(-/-) cells [1].